Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Pliant Therapeutics Inc (PLRX)

Pliant Therapeutics Inc (PLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,016,967
  • Shares Outstanding, K 48,682
  • Annual Sales, $ 7,570 K
  • Annual Income, $ -97,260 K
  • 60-Month Beta 1.47
  • Price/Sales 133.47
  • Price/Cash Flow N/A
  • Price/Book 5.12
Trade PLRX with:

Options Overview Details

View History
  • Implied Volatility 87.13% ( -0.47%)
  • Historical Volatility 64.54%
  • IV Percentile 44%
  • IV Rank 21.27%
  • IV High 219.97% on 05/11/22
  • IV Low 51.24% on 08/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 92
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 4,289
  • Open Int (30-Day) 4,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.74
  • Number of Estimates 5
  • High Estimate -0.67
  • Low Estimate -0.83
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +1.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.03 +15.86%
on 08/31/22
24.81 -15.80%
on 09/14/22
+2.78 (+15.35%)
since 08/30/22
3-Month
7.44 +180.78%
on 07/01/22
24.81 -15.80%
on 09/14/22
+12.88 (+160.80%)
since 06/30/22
52-Week
3.96 +426.86%
on 05/11/22
24.81 -15.80%
on 09/14/22
+4.01 (+23.76%)
since 09/30/21

Most Recent Stories

More News
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

MRK : 86.12 (-0.60%)
EBS : 20.99 (+1.01%)
INO : 1.7250 (+2.68%)
PLRX : 20.89 (+0.63%)
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.

JAZZ : 133.29 (+0.66%)
AXSM : 44.62 (+1.06%)
SESN : 0.4250 (+9.17%)
PLRX : 20.89 (+0.63%)
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?

Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.

PLRX : 20.89 (+0.63%)
TCRT : 1.7200 (-13.13%)
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?

Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PLRX : 20.89 (+0.63%)
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

VBLT : 0.1553 (-0.83%)
STRO : 5.55 (+2.21%)
PLRX : 20.89 (+0.63%)
IMCR : 46.94 (+2.40%)
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable,...

PLRX : 20.89 (+0.63%)
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

ABBV : 134.21 (-5.96%)
RYTM : 24.50 (+2.64%)
ANVS : 13.70 (+0.29%)
PLRX : 20.89 (+0.63%)
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

AZN : 54.84 (-0.13%)
SRNE : 1.5700 (-0.63%)
PLRX : 20.89 (+0.63%)
INZY : 2.68 (+3.47%)
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

BLUE : 6.33 (+11.05%)
RYTM : 24.50 (+2.64%)
PLRX : 20.89 (+0.63%)
INZY : 2.68 (+3.47%)
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

AGLE : 0.5260 (+7.37%)
RYTM : 24.50 (+2.64%)
PLRX : 20.89 (+0.63%)
INZY : 2.68 (+3.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO,...

See More

Key Turning Points

3rd Resistance Point 21.95
2nd Resistance Point 21.60
1st Resistance Point 21.25
Last Price 20.89
1st Support Level 20.55
2nd Support Level 20.20
3rd Support Level 19.85

See More

52-Week High 24.81
Last Price 20.89
Fibonacci 61.8% 16.85
Fibonacci 50% 14.39
Fibonacci 38.2% 11.93
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar